The FDA has approved a new EEG brain monitoring platform which can aid in the early detection of Alzheimer’s, Parkinson’s and dementia.
The Neurosteer® single-channel EEG brain monitoring platform has been given clearance by the FDA to be used in a range of clinical settings to help detect signs of common neurological disorders.
The unobtrusive multi-purpose system can aid doctors in the early detection of presymptomatic cognitive decline, including Alzheimer’s, Parkinson’s and dementia.
The platform can also be used in intensive care for continuous brain monitoring to support critical interventions, and in pharmaceutical drug trials, to assist in the rapid and cost-effective mass screening of subjects who may be suffering from neurodegenerative disorders.
Global health tech company, Neurosteer has advanced the century-old EEG machine into the 21st century, using an adhesive electrode strip connected to a pocket-sized sensor that wirelessly transmits EEG data to the cloud for advanced signal processing.
Using a single adhesive forehead strip, it offers the traditional EEG frequency bands while also being cleared by the FDA to include several novel ‘brain metrics’ visual representations.
These brain metrics rely on Neurosteer’s advanced signal processing technology and may assist trained medical staff in making neurological diagnoses.
In addition, affixing the adhesive strip to the forehead avoids interference from the hair, and using dry gel supports unattended operation for up to 12 hours.
The system also includes a noninvasive assessment with auditory prompts that can aid in the early detection of brain deterioration.
Dr Amitai Bickel, a surgeon at Western Galilee Hospital, commented: “After working with the Neurosteer EEG system for several years, I’ve realised what an advantage it is to have a compact, easy-to-apply EEG brain monitor that can be used for real-time continuous monitoring. Neurosteer’s innovative platform has the potential to revolutionise the standard of care in managing brain health.”
Neurosteer was founded in 2015 by Dr Nathan Intrator to commercialise the brain monitoring technology that he initially developed whilst at Tel Aviv University.
Dr Intrator added: “We are extremely pleased that the FDA has cleared our portable and affordable EEG system, and moreover, recognised the potential clinical value of our brain metrics visual representations.
“This is an important step in achieving our goal of making brain monitoring and assessment widely available to all populations.”
